Open-label, single-group Phase II study (n=15 actual) evaluating a single 25 mg dose of psilocybin with supportive therapy in adults with BP-II current depressive episode.
Open-label, single-group Phase II trial administering a single 25 mg oral dose of psilocybin with supportive psychotherapy to adults with bipolar II depression; primary objective is change in depressive symptoms.
Actual enrollment listed as 15. Outcomes include efficacy on depressive symptoms; safety and tolerability monitored under supportive conditions.
Open-label single-group administration of 25 mg psilocybin.
Open-label single 25 mg dose; supportive psychotherapy provided.